Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

Pain

Volumn 136, Issue 3, 2008, Pages 432-444

  Russell, I Jon ^a   Mease, Philip J ^b   Smith, Timothy R ^c   Kajdasz, Daniel K ^d   Wohlreich, Madelaine M ^d   Detke, Michael J ^d,e,f   Walker, Daniel J ^d   Chappell, Amy S ^d,e   Arnold, Lesley M ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Mercy Health Research   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Duloxetine; Efficacy and safety; Fibromyalgia; Randomized clinical trial

Indexed keywords

ACETYLSALICYLIC ACID; CHLORAL HYDRATE; DULOXETINE; HYPNOTIC SEDATIVE AGENT; PARACETAMOL; PLACEBO; ZALEPLON; ZOLPICLONE; ZOLPIDEM;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; HUMAN; HYPERHIDROSIS; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL ASSESSMENT; MYALGIA; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOMNOLENCE; SORE THROAT; TREATMENT OUTCOME; TREMOR; VITAL SIGN; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBO EFFECT; THIOPHENES; TREATMENT OUTCOME;

EID: 43549091316     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.02.024     Document Type: Article

References (45)

1. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., et al., for the Duloxetine Fibromyalgia Trial Group. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50 (2004) 2974-2984
2. Arnold L.M., Rosen A., Pritchett Y.L., D'Souza D.N., Goldstein D.J., Iyengar S., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119 (2005) 5-15
3. Basbaum A.I., and Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7 (1984) 309-338
4. Bech P., Kajdasz D.K., and Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 188 (2006) 273-280
5. Burckhardt C.S., Clark S.R., and Bennett R.M. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18 (1991) 728-733
6. Clark F.M., and Proudfit H.K. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res 616 (1993) 200-210
7. Clauw D.J., and Crofford L.J. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 17 (2003) 685-701
8. Cleeland C.S., and Ryan K.M. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23 (1994) 129-138
9. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., et al., and the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
10. Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., and Demitrack M.A. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63 (2002) 308-315
11. Detke M.J., Lu Y., Goldstein D.J., McNamara P.K., and Demitrack M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36 (2002) 383-390
12. Faries D., Herrera J., Rayamajhi J., DeBrota D., Demitrack M., and Potter W.Z. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 34 (2000) 3-10
13. Fischer A.A. Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil 67 (1986) 836-838
14. Gahimer J., Wernicke J., Yalcin I., Ossanna M.J., Wulster-Ratcliffe M., and Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 23 (2007) 175-184
15. Gendreau R.M., Thorn M.D., Gendreau J.F., Kranzler J.D., Ribeiro S., Gracely R.H., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32 (2005) 1975-1985
16. Goldstein D.J., Lu Y., Detke M.J., Lee T.C., and Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 (2005) 109-118
17. Greist J., McNamara R.K., Mallinckrodt C.H., Rayamajhi J.N., and Raskin J. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 26 (2004) 1446-1455
18. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville (MD): US Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
20. Hartford J., Kornstein S., Liebowitz M., Pigott T., Russell J., Detke M., et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22 (2007) 167-174
21. Hedges L.V., and Olkin I. Examination of a single effect size: parametric and nonparametric methods. Statistical methods for meta-analysis (1985), Academic Press Inc., Orlando, Florida 75-106
22. Holman A.J., and Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52 (2005) 2495-2505
23. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B. (Ed). Quality of life and pharmacoeconomics in clinical trials. 2nd ed. (1996), Lippincott-Raven Publishers, Philadelphia, PA 191-201
24. Koponen H., Allgulander C., Erickson J., Dunayevich E., Pritchett Y., Detke M.J., et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 9 (2007) 100-107
25. Mease P.J., Clauw D.J., Arnold L.M., Goldenberg D.L., Witter J., Williams D.A., et al. Fibromyalgia syndrome. J Rheumatol 32 (2005) 2270-2277
26. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 32 (2007) 6-21
27. Mease P., Arnold L.M., Bennett R., Boonen A., Buskila D., Carville S., et al. Fibromyalgia syndrome. J Rheumatol 34 (2007) 1415-1425
28. Millan M.J. Descending control of pain. Prog Neurobiol 66 (2002) 355-474
29. Raskin J., Pritchett Y.L., Wang F., D'Souza D.N., Waninger A.L., Iyengar S., et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6 (2005) 346-356
30. Retherford R.D., and Choe M.K. Statistical methods for causal analysis (1993), John Wiley and Sons, Inc., New York (NY)
31. Russell I.J., Vaeroy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35 (1992) 550-556
32. Russell I.J., Michalek J.E., Vipraio G.A., Fletcher E.M., Javors M.A., and Bowden C.A. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 19 (1992) 104-109
33. Sayar K., Aksu G., Ak I., and Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 37 (2003) 1561-1565
34. Sheehan D.V. The anxiety disease (1983), Charles Scribner and Sons, New York, NY
35. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (1998) 22-33
36. Smets E.M., Garssen B., Bonke B., and De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39 (1995) 315-325
37. Vitton O., Gendreau M., Gendreau J., Kranzler J., and Rao S.G. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19 (2004) S27-S35
38. Ware J.E., Snow K.K., Kosinski M., and Gandeck B. SF-36 health survey manual and interpretation guide (1993), The Health Institute, New England Medical Center, Boston (MA)
39. Wernicke J.F., Pritchett Y.L., D'Souza D.N., Waninger A.L., Tran P., Iyengar S., et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67 (2006) 1411-1420
40. Wernicke J.F., Lledo A., Raskin J., Kajdasz D.K., and Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 30 (2007) 437-455
41. Westfall P.H., and Krishen A. Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Stat Plan Infer 99 (2001) 25-40
42. White K.P., and Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 5 (2001) 320-329
43. Wolfe F., Ross K., Anderson J., Russell I.J., and Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 (1995) 19-28
44. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33 (1990) 160-172
45. Yunus M.B., Dailey J.W., Aldag J.C., Masi A.T., and Jobe P.C. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 19 (1992) 90-94